Status: Recruiting
To Evaluate HU-045 With Moderate to Severe Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Participants needed: 390
Trial details
Phase: Phase 3Age: 19-65Biological sex: AllType: InterventionalSponsor: Huons BiopharmaUpdated: Oct 13, 2026Locations: 1
Eligibility criteria
Adults aged 19 to 65 years, inclusive, as of the date of written informed consen... [+3]
Subjects with a known history of allergy or hypersensitivity to the investigatio... [+21]